Nicola A Hanania (Baylor College of Medicine, TX, US), a valued member of our Editorial Board, talks to us about maintenance therapies in chronic obstructive pulmonary disease (COPD) with a focus on dual and triple therapy approaches.
Questions1. Following the approval of triple therapy, what is the role of dual therapy in the treatment paradigm for chronic obstructive pulmonary disease (COPD)? (0:10)
2. What are the limitations of the clinical studies investigating the use of triple therapy? (1:30)
3. What advice would you give to clinicians in making the decision between dual and triple therapy? (2:21)
4. How do you expect triple therapy in COPD to evolve in the coming years? (3:16)
5. What are the indications for nebulized bronchodilator therapies in the treatment of patients with COPD? (3:53)
Speaker disclosure: Nicola A Hanania has received honoraria for serving on advisory boards or as a consultant for Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Novartis, and Sanofi/Regeneron. His institution has received research grant support on his behalf from Boehringer Ingelheim, AstraZeneca, Roche, and GlaxoSmithKline.
Filmed at the CHEST Annual Meeting, San Antonio, TX, US, October 2018.